Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05363449 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis
A Phase 1 study of Tinea Pedis and Tinea Cruris, sponsored by Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 5
- Study locations
NCT05363449: Completed Phase 1 study of Tinea Pedis and Tinea Cruris, sponsored by Therapeutics.
NCT05363449 is a Phase 1 study of Tinea Pedis and Tinea Cruris that has completed, run by Therapeutics. The registered enrollment target is 42 participants, below the 322-participant average among 9 other Tinea Pedis trials with a reported enrollment target (87% lower). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05363449, a Phase 1 study of Tinea Pedis and Tinea Cruris, has completed, sponsored by Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 5
- Study locations
Study Summary
This Phase 1 study has been designed to determine the safety, tolerability and pharmacokinetics (PK) of UHE 103 Cream compared to Naftin Cream, 2% under maximal use conditions for 2 weeks treatment in subjects with tinea cruris and/or tinea pedis
Primary Outcome
Percentage of subjects with any local and systemic AEs defined as "possibly" or "probably" or "definitely" related by the investigator.
Conditions Studied
Interventions
- DRUG UHE-103 Cream
- DRUG Naftin (naftifine hydrochloride) Cream
Study Locations (5)
Texas
- Site #2 - Austin
- Site #3 - College Station
- Site #4 - Houston
California
- Site #1 - San Diego
- Site #5 - Thousand Oaks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-02-17 |
| Est. Completion | 2023-11-14 |
| Phase | Phase 1 |
What the finished NCT05363449 record still lists
NCT05363449 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 322-participant average among 9 other Tinea Pedis trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Tinea Pedis appearing as the primary indexed condition, and to 2 interventions - of which UHE-103 Cream is the first listed.
NCT05363449 lists 5 locations in 2 states (Texas, California).
Frequently Asked Questions
What is clinical trial NCT05363449 about?
NCT05363449 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis". This Phase 1 study has been designed to determine the safety, tolerability and pharmacokinetics (PK) of UHE 103 Cream compared to Naftin Cream, 2% under maximal use conditions for 2 weeks treatment in subjects with tinea cruris and/or tinea pedis
What is the current status of trial NCT05363449?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2022-02-17. Estimated completion is 2023-11-14.
What conditions does trial NCT05363449 study?
This clinical trial studies the following conditions: Tinea Pedis, Tinea Cruris.
What interventions are being tested in trial NCT05363449?
The interventions under investigation include: UHE-103 Cream (DRUG), Naftin (naftifine hydrochloride) Cream (DRUG).
Who is sponsoring clinical trial NCT05363449?
This trial is sponsored by Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05363449 being conducted?
This trial has 5 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tinea Pedis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05363449's enrollment target sits among peer trials
42 10th of 9 the lowest of 9 other Tinea Pedis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tinea Pedis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study
RECRUITING · Phase 2
-
A Study of Econazole Foam 1% in Athlete's Foot
COMPLETED · Phase 2
-
Spread of Dermatophytes Among Families
COMPLETED
-
BE Study of Naftifine HCL
COMPLETED · Phase 3
-
A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
COMPLETED · Early Phase 1
-
Three-Arm Trial of Novel Treatment for Tinea Pedis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI